Sugi Predict

Sugi Predict / Compounds / SCHEMBL2520141

SCHEMBL2520141

SCHEMBL2520141

CS(=O)(=O)N1Cc2nc3c(N)nc4ccccc4c3n2[C@@H](CCCN)C1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 17/20 0.41
▸ TLR8 Q9NR97 10/20 0.41
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HRH2 P25021 1/20 0.37
▸ ADRA1D P25100 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADRA1A P35348 1/20 0.37
▸ NUDT1 P36639 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2512840 1.00 TLR7 (0.41) TLR7TLR8LMNAPOLBHRH2
Hydrochloric Acid SCHEMBL2510392 0.99 TLR7 (0.41) TLR7TLR8LMNAPOLBHRH2
SCHEMBL12020968 0.89 TLR7 (0.52) TLR7TLR8LMNAPOLBHRH2
SCHEMBL2513399 0.87 TLR7 (0.43) TLR7TLR8
SCHEMBL1775273 0.83 TLR7 (0.40) TLR7TLR8LMNAPOLBHRH2
SCHEMBL1773379 0.83 TLR7 (0.40) TLR7TLR8LMNAPOLBHRH2
SCHEMBL2511954 0.83 TLR7 (0.46) TLR7TLR8
SCHEMBL2513971 0.81 TLR7 (0.38) TLR7TLR8
Hydrochloric Acid SCHEMBL21074144 0.78 TLR7 (0.41) TLR7TLR8
Hydrochloric Acid SCHEMBL2513232 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350034-B2 Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-08 — — US disclosed
EP-1831221-B1 SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 — — EP disclosed
US-20110293654-A1 SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMANY 2011-12-01 — — US disclosed
US-8034938-B2 Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-10-11 — — US disclosed
US-20080085895-A1 Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds 3M INNOVATIVE PROPERTIES COMPANY 2008-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110293654-A1 SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNG, IL4, IFNAR1 TLR7 171/4885TLR8 359/4885LMNA 4409/4885
US-20080085895-A1 Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNG, IL4, IFNAR1 TLR7 171/4885TLR8 359/4885LMNA 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.